GSK Announces Positive Phase III EAGLE-1 Trial Results for Gepotidacin in Uncomplicated Urogenital Gonorrhoea

Gonorrhea is a disease caused bySexually transmitted diseases caused by Neisseria gonorrhoeae infection.IfUntimely or improper treatment, which may lead to infertility and other complications, and also increase the risk of HIV infection.It is estimated that there are 8,200 new cases globally each year.

EAGLE-1 StudyThe study evaluated GEpotidacin compared to ceftriaxone + azithromycin (GonorrheaMain AllianceTreatment Plan) Efficacy and safety in treating patients (n=600) with uncomplicated urogenital gonorrhea, with the primary endpoint being assessed 3-7 days post-treatment.At the Time of Cure Test (TOC) VisitMicrobiological Response。The results showed,The trial met the primary efficacy endpoint,AndCeftriaxone+AqiMold Combined RegimenIn comparison,gEpotidacin demonstrated non-inferiority, with detailed results to be announced at an upcoming medical conference.

GepotidacinDeveloped by GSKTargeting Topoisomerase II (Top II)First-in-Class NovelOral antibiotics, whose structure belongs toTriazacridine derivatives, distinct from existing quinolone antibiotics.Compared toQuinolone antibiotics (single inhibition of Top II or Top IV), gEpotidacin has a completely new mechanism of action, which canSelective and balanced inhibition of bacterial DNA gyrase (a type of Top II) and Top IV, thereby inhibiting bacterial DNA replication.Due to GEpotidacin forTop II and Top IV are balanced inhibitors; therefore, significant effects on bacterial resistance to g occur only when both enzymes are mutated.epotidacinSensitivity。

In addition to gonorrhea, GSK has also launchedgepotidacinClinical trials for the treatment of uncomplicated urinary tract infections (uUTI), including two pivotal Phase III studies(EAGLE-2 and EAGLE-3) have been achievedPositive data, soon to be submitted for market approval. The press release noted that if approved, gEpotidacin will becomeThe first new oral antibiotic for the treatment of uUTI in over 20 years.

Copyright © 2024 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

↑ Long pressScan the code, Register for the Salon ↑